The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma
The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma
复制标题
DOI：
10.1016/j.ygyno.2016.09.019
复制
发表时间：
2016-12-01
影响因子：
4.7
通讯作者：
Mc Nally, Amy
中科院分区：
文献类型：
--
作者：
Al-Niaimi, Ahmed;Dickson, Elizabeth L.;Mc Nally, Amy
客观的。量化围术期β受体阻滞剂的使用对上皮性卵巢癌初次细胞减灭术后生存的影响。方法。我们对所有因卵巢癌接受初次肿瘤细胞减灭术的女性（2000 年至 2010 年）进行了一项多中心回顾性研究。一家机构经常对“有冠状动脉事件风险”的患者使用围手术期阻滞剂。另一家机构没有常规使用围手术期阻滞剂。收集人口统计、手术和随访数据。 Cox 比例风险模型用于评估 β 受体阻滞剂对无进展间期 (PFI) 以及总生存期 (OS) 的影响。结果。在 185 名符合条件的患者中，70 名患者接受了 β 受体阻滞剂治疗，115 名患者接受了细胞减灭术，围手术期未使用受体阻滞剂。两组的人口统计数据相似。与未接受β受体阻滞剂的组相比，β受体阻滞剂组更常有高血压病史（22%和6%，p = 0.002）。 β 受体阻滞剂组的 PFI 更长，分别为 18.2 个月和 15.8 个月 (p = 0.66)。 beta blacker 组的 OS 显着较高，为 44.2 个月，而 39.3 个月 (p = 0.01)。在多变量分析中，围手术期使用 β-locker 与 OS 显着改善相关（HR 0.68 (0.46-0.99)；p = 0.046）。结论。我们的研究表明，接受原发性卵巢癌细胞减灭术的患者围手术期使用 β-ocker 与更长的总生存期之间存在关联。针对该人群的前瞻性随机临床试验将进一步验证这些结果。 (C) 2016 年，爱思唯尔公司出版
Objective. To quantify the impact of perioperative beta blocker use on survival after primary cytoreductive surgery for epithelial ovarian cancer.Methods. We conducted a multi-center retrospective study of all women who underwent primary cytoreductive surgery for ovarian cancer (2000 - 2010). One institution had routinely used perioperative blockers for patients "at risk" for coronary events. The other institution did not routinely use perioperative blockers. Demographic, operative, and follow up data were collected. Cox proportional hazards models were used to assess the effect of beta blockers on progression-free interval (PFI) as well as overall survival (OS).Results. Out of 185 eligible patients, 70 received beta blockers and 115 underwent cytoreductive surgery without perioperative blockers. Both groups were similar in demographics. A history of hypertension was present more often in the beta blocker group compared to the group that did not receive beta blockers (22% and 6%, p = 0.002). PFI in beta blocker group was greater at 18.2 vs. 15.8 months (p = 0.66). The OS in the beta blacker group was significantly higher at 44.2 vs. 39.3 months (p = 0.01). In multivariate analysis, perioperative beta locker use was associated with significant improvement in OS (HR 0.68 (0.46-0.99); p = 0.046).Conclusion. Our study showed an association between perioperative beta ocker use and.longer overall survival in patients undergoing primary ovarian cancer cytoreductive surgery. A prospective randomized clinical trial in this population would further validate these results. (C) 2016 Published by Elsevier Inc.